title: [Efficacy of Helicobacter pylori eradication in non-ulcer dyspepsia].
abstract: OBJECTIVE
  The relationship between Helicobacter pylori infection and functional dyspepsia (FD) is disputed. Although there is a greater prevalence of infection by H. pylori in subjects with non-ulcer dyspepsia than in healthy subjects, results regarding the eradication of infection have been inconclusive so far in terms of disease improvement. In this study, we administered eradicating treatment to a group of patients with both FD and infection by H. pylori to determine the possible beneficial effect of such a treatment. Thus, our objective was to study the effectiveness of eradication therapy for H. pylori in the clinical course of FD.
  
  
  METHODS
  This was a randomized, double-blind study in 93 consecutive patients diagnosed with FD and infection by H. pylori who received eradicating treatment with omeprazol, amoxicillin and clarythromicin for 7 days (group A, n = 47) vs. placebo, amoxicillin and clarythromicin for 7 days (group B, n = 46). We analyzed the clinical evolution of the disease within the following 9 months.
  
  
  RESULTS
  Both groups of treatment were comparable concerning all the variables studied except for the consumption of alcohol, with a greater prevalence in group A, yet no patient consumed more than 40 g per day. The average age of patients was 42 (18-65). Eradication of H. pylori occurred in 65.9% of patients in group A and 4.3% of patients in group B. 40% of all patients included in the study had improved symptoms. In 60.6% of patients whose infection was eradicated, their symptoms improved, as opposed to 25% of patients whose infection was not eradicated (p = 0.001). Among patients whose symptoms improved following eradication, 70% had had an FD duration of less than 3 years and in 30% FD had lasted for more than 3 years (p < 0.05).
  
  
  CONCLUSIONS
  The eradication of H. pylori in patients with short-lasting FD may lead to a significant clinical benefit, especially in those whose duration of symptoms is below 3 years.
authors.affiliation: Hospital General Mancha-Centro. Alcázar de San Juan. Ciudad Real. España. psgc@mixmail.com
authors.forename: Pedro
authors.initials: P
authors.lastname: González Carro
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Legaz Huidobro
authors.forename: Francisco
authors.initials: F
authors.lastname: Pérez Roldán
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Esteban López Jamar
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Valenzuela Gámez
authors.forename: Ana
authors.initials: A
authors.lastname: Ponte Tellechea
authors.forename: Francisco
authors.initials: F
authors.lastname: Ruiz Carrillo
authors.forename: Carmen
authors.initials: C
authors.lastname: Pedraza Martín
authors.forename: Francisco
authors.initials: F
authors.lastname: Díaz de Rojas
authors.forename: José M
authors.initials: JM
authors.lastname: Sáez Bravo
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D005765:Gastrointestinal Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole